AIMS: A descriptive survey of published population pharmacokinetic and/or pharmacodynamic (PK/PD) analyses from 2002 to 2004 was conducted and an evaluation made of how model building was performed and reported. METHODS: We selected 324 articles in Pubmed using defined keywords. A data abstraction form (DAF) was then built comprising two parts: general characteristics including article identification, context of the analysis, description of clinical studies from which the data arose, and model building, including description of the processes of modelling. The papers were examined by two readers, who extracted the relevant information and transmitted it directly to a MySQL database, from which descriptive statistical analysis was performed. RESULTS: Most published papers concerned patients with severe pathology and therapeutic classes suffering from narrow therapeutic index and/or high PK/PD variability. Most of the time, modelling was performed for descriptive purposes, with rich rather than sparse data and using NONMEM software. PK and PD models were rarely complex (one or two compartments for PK; E(max) for PD models). Covariate testing was frequently performed and essentially based on the likelihood ratio test. Based on a minimal list of items that should systematically be found in a population PK-PD analysis, it was found that only 39% and 8.5% of the PK and PD analyses, respectively, published from 2002 to 2004 provided sufficient detail to support the model-building methodology. CONCLUSIONS: This survey allowed an efficient description of recent published population analyses, but also revealed deficiencies in reporting information on model building.
AIMS: A descriptive survey of published population pharmacokinetic and/or pharmacodynamic (PK/PD) analyses from 2002 to 2004 was conducted and an evaluation made of how model building was performed and reported. METHODS: We selected 324 articles in Pubmed using defined keywords. A data abstraction form (DAF) was then built comprising two parts: general characteristics including article identification, context of the analysis, description of clinical studies from which the data arose, and model building, including description of the processes of modelling. The papers were examined by two readers, who extracted the relevant information and transmitted it directly to a MySQL database, from which descriptive statistical analysis was performed. RESULTS: Most published papers concerned patients with severe pathology and therapeutic classes suffering from narrow therapeutic index and/or high PK/PD variability. Most of the time, modelling was performed for descriptive purposes, with rich rather than sparse data and using NONMEM software. PK and PD models were rarely complex (one or two compartments for PK; E(max) for PD models). Covariate testing was frequently performed and essentially based on the likelihood ratio test. Based on a minimal list of items that should systematically be found in a population PK-PD analysis, it was found that only 39% and 8.5% of the PK and PD analyses, respectively, published from 2002 to 2004 provided sufficient detail to support the model-building methodology. CONCLUSIONS: This survey allowed an efficient description of recent published population analyses, but also revealed deficiencies in reporting information on model building.
Authors: Ch Van Kesteren; R A A Mathôt; E Raymond; J P Armand; Ch Dittrich; H Dumez; H Roché; J P Droz; C Punt; M Ravic; J Wanders; J H Beijnen; P Fumoleau; J H M Schellens Journal: J Clin Oncol Date: 2002-10-01 Impact factor: 44.544
Authors: Salmaan Kanji; Meghan Hayes; Adam Ling; Larissa Shamseer; Clarence Chant; David J Edwards; Scott Edwards; Mary H H Ensom; David R Foster; Brian Hardy; Tyree H Kiser; Charles la Porte; Jason A Roberts; Rob Shulman; Scott Walker; Sheryl Zelenitsky; David Moher Journal: Clin Pharmacokinet Date: 2015-07 Impact factor: 6.447
Authors: Malidi Ahamadi; Anna Largajolli; Paul M Diderichsen; Rik de Greef; Thomas Kerbusch; Han Witjes; Akshita Chawla; Casey B Davis; Ferdous Gheyas Journal: J Pharmacokinet Pharmacodyn Date: 2019-04-24 Impact factor: 2.745